The French Supreme Administrative Court annuls a State’s decision discriminating the reimbursement’s rate between princeps and generic drugs (GlaxoSmithKline)

1. The Regulatory Context: positive discrimination as a starting point and the TFR a possible end to it Sales of reimbursable medicines to consumers are heavily regulated in France, from the level of the pharmaceutical company manufacturing them all the way through to the ultimate individual purchaser, via wholesalers and pharmacists. Before marketing a drug, any pharmaceutical company manufacturing princeps will have to negotiate its public retail prices (and reimbursement level) with the public authorities [1] ; on the other hand, a pharmaceutical company manufacturing generics will have its prices automatically accepted provided that these prices are at least 30-40% lower than the princeps' price. Hence, the first generics to penetrate a "market" where a patent has expired are

L'accès à cet article est réservé aux abonnés

Déjà abonné ? Identifiez-vous

L’accès à cet article est réservé aux abonnés.

Lire gratuitement un article

Vous pouvez lire cet article gratuitement en vous inscrivant.

 

Version PDF

Auteurs

Citation

Olivier Fréget, Fleur Herrenschmidt, The French Supreme Administrative Court annuls a State’s decision discriminating the reimbursement’s rate between princeps and generic drugs (GlaxoSmithKline), 11 juin 2007, e-Competitions June 2007, Art. N° 13770

Visites 4262

Tous les numéros

  • Latest News issue 
  • Tous les News issues
  • Latest Special issue 
  • Tous les Special issues